Dublin, Dec. 22, 2016 -- Research and Markets has announced the addition of the "Chronic Pain Drugs Price Analysis and Strategies - 2016" report to their offering.
Chronic Pain Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Chronic Pain market.
The research answers the following questions:
- What are the key drugs marketed for Chronic Pain and their clinical attributes? How are they positioned in the Global Chronic Pain market?
- What are the unit prices and annual treatment cost for Chronic Pain therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Chronic Pain drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Chronic Pain?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Chronic Pain including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Chronic Pain
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Chronic Pain market
- Chronic Pain Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Chronic Pain New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/p68dtk/chronic_pain
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Analgesics


SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 



